Our top pick for
ResMed Inc is a medical instruments & supplies business based in the US. ResMed shares (RMD) are listed on the NYSE and all prices are listed in US Dollars. ResMed employs 7,770 staff and has a trailing 12-month revenue of around USD$3.1 billion.
|52-week range||USD$112.5045 - USD$223.9921|
|50-day moving average||USD$209.1268|
|200-day moving average||USD$195.1915|
|Wall St. target price||USD$214.6|
|Dividend yield||USD$1.56 (0.78%)|
|Earnings per share (TTM)||USD$4.79|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing ResMed stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ResMed's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
ResMed's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 42x. In other words, ResMed shares trade at around 42x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
ResMed's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.0721. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into ResMed's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
ResMed's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$1 billion.
The EBITDA is a measure of a ResMed's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$3.1 billion|
|Operating margin TTM||28.98%|
|Gross profit TTM||USD$1.8 billion|
|Return on assets TTM||12.55%|
|Return on equity TTM||27.28%|
|Market capitalisation||USD$29.1 billion|
TTM: trailing 12 months
There are currently 1.1 million ResMed shares held short by investors – that's known as ResMed's "short interest". This figure is 0.8% up from 1.1 million last month.
There are a few different ways that this level of interest in shorting ResMed shares can be evaluated.
ResMed's "short interest ratio" (SIR) is the quantity of ResMed shares currently shorted divided by the average quantity of ResMed shares traded daily (recently around 463306.38297872). ResMed's SIR currently stands at 2.35. In other words for every 100,000 ResMed shares traded daily on the market, roughly 2350 shares are currently held short.
However ResMed's short interest can also be evaluated against the total number of ResMed shares, or, against the total number of tradable ResMed shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ResMed's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 ResMed shares in existence, roughly 10 shares are currently held short) or 0.0085% of the tradable shares (for every 100,000 tradable ResMed shares, roughly 9 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ResMed.
Find out more about how you can short ResMed stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like ResMed.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 29.05
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and ResMed's overall score of 29.05 (as at 01/01/2019) is nothing to write home about – landing it in it in the 50th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like ResMed is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 7.42/100
ResMed's environmental score of 7.42 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that ResMed is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 14/100
ResMed's social score of 14 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that ResMed is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 12.64/100
ResMed's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that ResMed is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. ResMed scored a 1 out of 5 for controversy – the highest score possible, reflecting that ResMed has managed to keep its nose clean.
|Total ESG score||29.05|
|Total ESG percentile||50.28|
|Environmental score percentile||4|
|Social score percentile||4|
|Governance score percentile||4|
|Level of controversy||1|
Dividend payout ratio: 29.43% of net profits
Recently ResMed has paid out, on average, around 29.43% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.78% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), ResMed shareholders could enjoy a 0.78% return on their shares, in the form of dividend payments. In ResMed's case, that would currently equate to about $1.56 per share.
While ResMed's payout ratio might seem fairly standard, it's worth remembering that ResMed may be investing much of the rest of its net profits in future growth.
ResMed's most recent dividend payout was on 18 March 2021. The latest dividend was paid out to all shareholders who bought their shares by 10 February 2021 (the "ex-dividend date").
ResMed's shares were split on a 2:1 basis on 31 August 2010. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your ResMed shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for ResMed shares which in turn could have impacted ResMed's share price.
Over the last 12 months, ResMed's shares have ranged in value from as little as $112.5045 up to $223.9921. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while ResMed's is 0.3228. This would suggest that ResMed's shares are less volatile than average (for this exchange).
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.